Evidence map›Paper›PMID 29170909›Full record

ArticleJournal of neuro-oncology2018

New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model.

Nundia Louis, Sharon Liu, Xingyao He, Daryl C Drummond, Charles O Noble, Stewart Goldman, Sabine Mueller, Krystof Bankiewicz, Nalin Gupta, Rintaro Hashizume

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Nundia LouisDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, 300 East Superior Street, Tarry 2-709, Chicago, IL, 60611, USA.
Sharon LiuBrain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Xingyao HeDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, 300 East Superior Street, Tarry 2-709, Chicago, IL, 60611, USA.
Daryl C DrummondMerrimack, Cambridge, MA, USA.
Charles O NobleMerrimack, Cambridge, MA, USA.
Stewart GoldmanDepartment of Pediatrics - Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Sabine MuellerDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Krystof BankiewiczBrain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Nalin GuptaBrain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9539-7052
Rintaro HashizumeDepartment of Neurological Surgery, Northwestern University Feinberg School of Medicine, 300 East Superior Street, Tarry 2-709, Chicago, IL, 60611, USA. Rintaro.hashizume@northwestern.edu.
University of California, San Francisco · USNorthwestern University · USMerrimack Pharmaceuticals (United States) · USLurie Children's Hospital · US

Funding

Targeting histone demethylase activity for the treatment of pediatric brainstem gliomaR01NS093079 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HASHIZUME, RINTARO · 2015 to 2019
$1.5M
Foundation for the National Institutes of Health RO1NS093079NINDS NIH HHS R01 NS093079Pediatric Brain Tumor Foundation n/a
6 · The paper itself

Abstract

Despite the advances in imaging, surgery and radiotherapy, the majority of patients with brainstem gliomas die within 2 years after initial diagnosis. Factors that contribute to the dismal prognosis of these patients include the infiltrative nature and anatomic location in an eloquent area of the brain, which prevents total surgical resection and the presence of the blood-brain barrier (BBB), which reduces the distribution of systemically administered agents. The development of new therapeutic approaches which can circumvent the BBB is a potential path to improve outcomes for these children. Convection-enhanced delivery (CED) and intranasal delivery (IND) are strategies that permit direct drug delivery into the central nervous system and are an alternative to intravenous injection (IV). We treated rats bearing human brainstem tumor xenografts with nanoliposomal irinotecan (CPT-11) using CED, IND, and IV. A single treatment of CED irinotecan had a similar effect on overall survival as multiple treatments by IV route. IND CPT-11 showed significantly increased survival of animals with brainstem tumors, and demonstrated the promise of this non-invasive approach of drug delivery bypassing the BBB when combined with nanoliposomal chemotherapy. Our results indicated that using CED and IND of nanoliposomal therapy increase likelihood of practical therapeutic approach for the treatment of brainstem gliomas.

Indexed as

Administration, IntranasalAnimalsBrain Stem NeoplasmsCell Line, TumorConvectionDrug CarriersHumansIrinotecanLiposomesMaleNanostructuresRatsTopoisomerase I InhibitorsXenograft Model Antitumor AssaysDrug CarriersIrinotecanLiposomesTopoisomerase I InhibitorsBrainstem gliomaConvection-enhanced delivery (CED)Intranasal delivery (IND)Irinotecan (CPT-11)Xenograft model

Identifiers

PMID29170909
PMCPMC5807192
OpenAlexW2770267914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.